Trifolium Bio-B (02197) released its interim results for the six months ending June 30, 2024, during which the group...
According to the Trifolium Bio-B (02197) announcement, the group recorded a loss of 10.1 million yuan (RMB) for the six-month period ending June 30, 2024, compared to a profit of 0.257 million yuan in the same period last year. Shareholders' loss was 95.123 million yuan for the current period, compared to a shareholders' profit of 0.651 billion yuan in the same period last year, resulting in a loss in year-on-year comparison. The basic loss per share was 0.08 yuan.
According to the announcement, the negative revenue of approximately 10.1 million yuan was due to the return of the quadrivalent influenza vaccine AdimFlu-S during the reporting period.